A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
Status:
Active, not recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The OReO study will be a Phase IIIb, randomised, double-blind, placebo-controlled,
multicentre study to assess the efficacy and tolerability of Olaparib retreatment, versus
matching placebo, in non-mucinous epithelial ovarian cancer (EOC) patients (including
patients with primary peritoneal and/or fallopian tube cancer).
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborators:
European Network of Gynaecological Oncological Trial Groups (ENGOT) European Network of Gynaecological Oncology Trial Groups (ENGOT)